Abstract: Objective To study the clinical effects and safety of continuous plasma exchange and hemodiafiltration on the patients with severe hepatitis. Methods All the patients enrolled suffered from severe hepatitis. Fourty-one cases in the treatment group(34 cases with chronic severe hepatitis B) were treated with continuous plasma change and hemodiafiltration. Except routine therapy, an additional artificial liver support system of KM-8900 purfusion device made in Japan was used to treat the treatment group patients. Thirty-seven cases in the control group (32 cases with chronic severe hepatitis B) were treated with plasma exchange. Patients in both groups suffered from some complications. Results Of all 41 patients in the treatment group, the total survival rate was 51.22%(21/41), and the survival rate of control group was 32.43%. The difference was significant (P＜0.05). In the treatment group patients,dialysis disorder were improved effectively, and their urea, creatine, NH3 in serum decreased obviously, but not in the control group (P＜0.01). The volums of plasma used or discarded by the treatment group patients were obviously less than that of the control group(P＜0.01).Although the average content of serum total bilirubin of the treatment group patients decreased more than that of the control group patients at the end of the study, the difference was insignificant. While the content of serum total bilirubin increased less than that of the control group patients 48 hours after therapy (P＜0.05). Conclusion Continuous plasma diafiltration is safe and effective. It can improve the symptoms and blood parameters of severe hepatitis patients delay the serum bilirubin re-bounce and efficiently increase survival rate. It is worthwhile to be wide spread.

Key words: Hemodiafiltration, Severe hepatitis